Colon adenocarcinoma and Birt–Hogg–Dubé syndrome in a young patient: case report and exploration of pathologic implications

ABSTRACT Birt–Hogg–Dubé syndrome (BHD) is an autosomal dominant disorder caused by germline mutations in the folliculin gene (FLCN) that result in the functional loss of the tumor suppressor folliculin. It is classically associated with cutaneous hamartomas, pulmonary cysts with spontaneous pneumothorax, and various renal cancers. In this case, we present a patient initially diagnosed with chromophobe renal cell carcinoma and subsequently found to have colorectal cancer (CRC). The presence of two separate malignancies in a young patient with a strong family history of CRC (father and paternal grandfather) led to genetic testing, which revealed an FLCN c.1177–5_1177-3del mutation, and a diagnosis of BHD was made. Out of the more than 300 known unique mutations of the FLCN coding region, the c.1285dupC mutation on exon 11 has been the only one convincingly associated with CRC thus far. While larger cohort studies are needed to further clarify this association, we present the first patient with CRC to our knowledge with an FLCN c.1177–5_1177-3del mutation and loss of heterozygosity implicating it as an initiating factor in tumorigenesis. We further explore the studies supporting and refuting the connection between BHD and CRC and highlight the molecular signaling pathways that may play a role in pathogenesis.

[1]  W. Linehan,et al.  Seventh BHD international symposium: recent scientific and clinical advancement , 2022, Oncotarget.

[2]  W. Linehan,et al.  The tumor suppressor folliculin inhibits lactate dehydrogenase A and regulates the Warburg effect , 2021, Nature Structural & Molecular Biology.

[3]  E. Sattler,et al.  Colorectal cancer risk in families with Birt-Hogg-Dubé syndrome increased. , 2021, European journal of cancer.

[4]  T. Hofmann,et al.  The Role of p53 Signaling in Colorectal Cancer , 2021, Cancers.

[5]  J. Nemunaitis,et al.  Adenomatous polyposis coli in cancer and therapeutic implications , 2021, Oncology reviews.

[6]  L. Ricciardiello,et al.  Are Wnt/β-Catenin and PI3K/AKT/mTORC1 Distinct Pathways in Colorectal Cancer? , 2020, Cellular and molecular gastroenterology and hepatology.

[7]  H. Meijers-Heijboer,et al.  No evidence for increased prevalence of colorectal carcinoma in 399 Dutch patients with Birt-Hogg-Dubé syndrome , 2019, British Journal of Cancer.

[8]  A. Wysong,et al.  Laser-Assisted Delivery of Topical Rapamycin: mTOR Inhibition for Birt-Hogg-Dube Syndrome. , 2019, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[9]  R. Müller,et al.  Characterization of a splice-site mutation in the tumor suppressor gene FLCN associated with renal cancer , 2017, BMC Medical Genetics.

[10]  L. Schmidt,et al.  H255Y and K508R missense mutations in tumour suppressor folliculin (FLCN) promote kidney cell proliferation , 2016, Human molecular genetics.

[11]  Philip F. Hughes,et al.  The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding , 2016, Nature Communications.

[12]  A. Lencastre,et al.  Birt-Hogg-Dubé syndrome* , 2013, Anais brasileiros de dermatologia.

[13]  A. Pause,et al.  Birt–Hogg–Dubé: tumour suppressor function and signalling dynamics central to folliculin , 2013, Familial Cancer.

[14]  M. Arends Pathways of Colorectal Carcinogenesis , 2013, Applied immunohistochemistry & molecular morphology : AIMM.

[15]  I. Tomlinson,et al.  Investigation of the Birt–Hogg–Dubé tumour suppressor gene (FLCN) in familial and sporadic colorectal cancer , 2010, Journal of Medical Genetics.

[16]  T. Kobayashi,et al.  Interaction of folliculin (Birt-Hogg-Dubé gene product) with a novel Fnip1-like (FnipL/Fnip2) protein , 2008, Oncogene.

[17]  J. Hartley,et al.  Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling , 2006, Proceedings of the National Academy of Sciences.

[18]  W. Linehan,et al.  High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. , 2005, Journal of the National Cancer Institute.

[19]  S. Richard,et al.  Clinical and genetic studies of Birt-Hogg-Dubé syndrome , 2002, Journal of medical genetics.

[20]  Maria Merino,et al.  Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. , 2002, Cancer cell.

[21]  P. Choyke,et al.  Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[22]  B. Zbar,et al.  Birt-Hogg-Dubé syndrome: a novel marker of kidney neoplasia. , 1999, Archives of dermatology.

[23]  M. Benson,et al.  Bilateral renal cell carcinoma in the Birt-Hogg-Dubé syndrome. , 1993, Journal of the American Academy of Dermatology.

[24]  W. J. Dubé,et al.  Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. , 1977, Archives of dermatology.

[25]  Thierry Soussi,et al.  APC gene: database of germline and somatic mutations in human tumors and cell lines , 1996, Nucleic Acids Res..